Joyce Angélica de Oliveira
Research Subjects
Research Interests
Joyce Angélica de Oliveira has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Carla Luciana Batista
Hospital Israelita Albert Einstein - São Paulo (SP), Brazil
1 shared publication - Erica Albanez Giovanetti1 shared publication
- Flavia Sales Leite1 shared publication
- Gustavo Brasil Marcelino1 shared publication
- Henrique Gerardus van der Laan1 shared publication
- Karina Santos Vieira1 shared publication
Latest Publications
- Open Access
- 15 August 2023
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 21 (Suppl 1)
Tetraplegy due to intermittent acute porphyria: the role of physiotherapy in the rehabilitation process – a case report
III Einstein International Symposium on Intensive Care and the XXX International Symposium on Mechanical Ventilation. Aug 16-18, 2023. Category: Neurology Introduction: Acute Intermittent Porphyria (AIP) is one subtype, out of eight, that encompasses the porphyria. Each subtype is secondary to a defect in the pathway of Heme synthesis. AIP is an autosomal-dominant disease, manifested in less than 10% of individuals with the mutation. The clinical presentation varies, and involves a range of symptoms from abdominal pain to important muscular paralysis,
- 15 August 2023
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 21 (Suppl 1)
Open AccessTetraplegy due to intermittent acute porphyria: the role of physiotherapy in the rehabilitation process – a case report
III Einstein International Symposium on Intensive Care and the XXX International Symposium on Mechanical Ventilation. Aug 16-18, 2023. Category: Neurology Introduction: Acute Intermittent Porphyria (AIP) is one subtype, out of eight, that encompasses the porphyria. Each subtype is secondary to a defect in the pathway of Heme synthesis. AIP is an autosomal-dominant disease, manifested in less than 10% of individuals with the mutation. The clinical presentation varies, and involves a range of symptoms from abdominal pain to important muscular paralysis,